477 related articles for article (PubMed ID: 18805512)
41. Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks.
Sallmyr A; Tomkinson AE; Rassool FV
Blood; 2008 Aug; 112(4):1413-23. PubMed ID: 18524993
[TBL] [Abstract][Full Text] [Related]
42. Loss of histone H2AX increases sensitivity of immortalized mouse fibroblasts to the topoisomerase II inhibitor etoposide.
Donà F; Prosperi E; Savio M; Coppa T; Scovassi AI; Mondello C
Int J Oncol; 2008 Sep; 33(3):613-21. PubMed ID: 18695893
[TBL] [Abstract][Full Text] [Related]
43. The G2-phase decatenation checkpoint is defective in Werner syndrome cells.
Franchitto A; Oshima J; Pichierri P
Cancer Res; 2003 Jun; 63(12):3289-95. PubMed ID: 12810661
[TBL] [Abstract][Full Text] [Related]
44. Accumulation of Werner protein at DNA double-strand breaks in human cells.
Lan L; Nakajima S; Komatsu K; Nussenzweig A; Shimamoto A; Oshima J; Yasui A
J Cell Sci; 2005 Sep; 118(Pt 18):4153-62. PubMed ID: 16141234
[TBL] [Abstract][Full Text] [Related]
45. Werner syndrome helicase (WRN), nuclear DNA helicase II (NDH II) and histone gammaH2AX are localized to the centrosome.
Zhang S; Hemmerich P; Grosse F
Cell Biol Int; 2007 Oct; 31(10):1109-21. PubMed ID: 17498979
[TBL] [Abstract][Full Text] [Related]
46. Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro.
Stahl M; Kasimir-Bauer S; Harstrick A
Anticancer Drugs; 1997 Aug; 8(7):671-6. PubMed ID: 9311443
[TBL] [Abstract][Full Text] [Related]
47. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
Ling YH; Andersson BS; Nelson JA
Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843
[TBL] [Abstract][Full Text] [Related]
48. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage.
Adachi N; Suzuki H; Iiizumi S; Koyama H
J Biol Chem; 2003 Sep; 278(38):35897-902. PubMed ID: 12842886
[TBL] [Abstract][Full Text] [Related]
49. HIF-1alpha modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines.
Choi YJ; Rho JK; Lee SJ; Jang WS; Lee SS; Kim CH; Lee JC
J Cancer Res Clin Oncol; 2009 Aug; 135(8):1047-53. PubMed ID: 19148680
[TBL] [Abstract][Full Text] [Related]
50. WRN, the protein deficient in Werner syndrome, plays a critical structural role in optimizing DNA repair.
Chen L; Huang S; Lee L; Davalos A; Schiestl RH; Campisi J; Oshima J
Aging Cell; 2003 Aug; 2(4):191-9. PubMed ID: 12934712
[TBL] [Abstract][Full Text] [Related]
51. The role of WRN in DNA repair is affected by post-translational modifications.
Kusumoto R; Muftuoglu M; Bohr VA
Mech Ageing Dev; 2007 Jan; 128(1):50-7. PubMed ID: 17116323
[TBL] [Abstract][Full Text] [Related]
52. RECQL5 plays co-operative and complementary roles with WRN syndrome helicase.
Popuri V; Huang J; Ramamoorthy M; Tadokoro T; Croteau DL; Bohr VA
Nucleic Acids Res; 2013 Jan; 41(2):881-99. PubMed ID: 23180761
[TBL] [Abstract][Full Text] [Related]
53. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
Ellis AL; Nowak B; Plunkett W; Zwelling LA
Cancer Chemother Pharmacol; 1994; 34(3):249-56. PubMed ID: 8004759
[TBL] [Abstract][Full Text] [Related]
54. Emodin triggers DNA double-strand breaks by stabilizing topoisomerase II-DNA cleavage complexes and by inhibiting ATP hydrolysis of topoisomerase II.
Li Y; Luan Y; Qi X; Li M; Gong L; Xue X; Wu X; Wu Y; Chen M; Xing G; Yao J; Ren J
Toxicol Sci; 2010 Dec; 118(2):435-43. PubMed ID: 20855424
[TBL] [Abstract][Full Text] [Related]
55. A novel peroxisome proliferator-activated receptor alpha/gamma agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells.
Kao YH; Hsieh HP; Chitlimalla SK; Pan WY; Kuo CC; Tsai YC; Lin WH; Chuang SE; Chang JY
Anticancer Drugs; 2008 Feb; 19(2):151-8. PubMed ID: 18176111
[TBL] [Abstract][Full Text] [Related]
56. p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine.
Furuta T; Hayward RL; Meng LH; Takemura H; Aune GJ; Bonner WM; Aladjem MI; Kohn KW; Pommier Y
Oncogene; 2006 May; 25(20):2839-49. PubMed ID: 16407843
[TBL] [Abstract][Full Text] [Related]
57. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
[TBL] [Abstract][Full Text] [Related]
58. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
Bruzzese F; Rocco M; Castelli S; Di Gennaro E; Desideri A; Budillon A
Mol Cancer Ther; 2009 Nov; 8(11):3075-87. PubMed ID: 19887547
[TBL] [Abstract][Full Text] [Related]
59. Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin.
Wu J; Yin MB; Hapke G; Tóth K; Rustum YM
Mol Pharmacol; 2002 Apr; 61(4):742-8. PubMed ID: 11901212
[TBL] [Abstract][Full Text] [Related]
60. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
Sorensen M; Sehested M; Jensen PB
Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
